The chart looks very encouraging to me.
I recall amstock posting that ~80% of people carry the wild type sigma1r receptor, so that will limit poor responders in the general population to about twenty percent.
Either amstock or falconer (or both) have explained -- this seems obvious -- that 2-73 has less opportunity to act effectively where Alzheimer's severity has progressed to the point where a great number of neurons are already irrerievably lost (my paraphrase). Consider the MMSE score of above or below 20 as a proxy for measuring this element.
Finally, the chart shows dose dependency, with higher dosed subjects performing better.
Therefore, if Anavex uses the effective 2-73 dose on mild to moderate ALZ patients (MMSE above or equal to 20) and the numbers replicate with an appropriately sufficient n, we should see a stat sig benefit, over and above current Standard of Care, in about 80% of case on the cognitive and behavioral measures.
Why would that not be a blockbuster?
Market Data 
Markets 
AI
